JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic and survival factors in head and neck extra-nodal non-Hodgkin's lymphoma

  • 0Department of Surgery and Medical-Surgical Specialties, School of Medicine and Dentistry, Universidade de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology +

|

October 9, 2024

|

October 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study characterizes head and neck non-Hodgkin lymphomas, finding good survival rates with immunochemotherapy. Key prognostic factors include hemoglobin, ß2-microglobulin, lactate dehydrogenase (LDH), ECOG, stage, and B symptoms.

Area Of Science

  • Oncology
  • Hematology
  • Clinical Medicine

Background

  • Extranodal non-Hodgkin lymphomas (NHL) of the head and neck are rare but significant clinical entities.
  • Understanding their clinical-biological characteristics and prognostic factors is crucial for effective patient management.

Purpose Of The Study

  • To provide a detailed clinical-biological characterization of primary extranodal head and neck NHL.
  • To assess patient survival rates and identify associated prognostic factors.

Main Methods

  • Retrospective observational study of 145 patients diagnosed between 2005 and 2016.
  • Inclusion criteria: primary extranodal NHL of the head and neck with single tumor in situ or clinically predominant extranodal component.
  • Data analysis focused on clinical presentation, treatment, survival, and prognostic indicators.

Main Results

  • Localized stages (I-II) accounted for 69.3% of cases; 91.8% were B-cell phenotype, most commonly diffuse large B-cell lymphoma.
  • Overall survival at 3 and 5 years was 75% and 73%, respectively; progression-free survival was 71% and 68%.
  • Adverse prognostic factors identified: low hemoglobin, elevated ß2-microglobulin, elevated lactate dehydrogenase (LDH), advanced Eastern Cooperative Oncology Group (ECOG) performance status, advanced stage (III-IV), and B symptomatology.

Conclusions

  • Primary extranodal head and neck NHL shows a favorable response to immunochemotherapy.
  • Prognosis is significantly influenced by baseline hemoglobin, ß2-microglobulin, LDH levels, ECOG performance status, disease stage, and the presence of B symptoms at diagnosis.